Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndamax and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Last trade$28.44
Day change-$0.42 (-1.46%)
Day range$28.38 – $28.86
Volume16,415,838
Market cap$164.50B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$164.5B
Price / earnings
40.79×
Price / book
1.85×
Price / sales
2.59×
EV / sales
3.54×
EV / EBITDA
9.75×
Profitability
Earnings per share
$0.71
Return on assets
1.97%
Return on equity
4.53%
Dividend yield
5.95%
Liquidity and leverage
Debt / equity
0.7×
Current ratio
1.42×
Quick ratio
1.1×
Cash ratio
0.06×
Cash flow
Price / cash flow
11.61×
Price / free cash flow
13.96×
Free cash flow
$11.79B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PFE, quarterly periods
Line item
Q3 FY2026 Sep 27, 2026
Q2 FY2026 Jun 28, 2026
Q1 FY2026 Mar 29, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 28, 2025
Q2 FY2025 Jun 29, 2025
Q1 FY2025 Mar 30, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$16.58B
$15.03B
$14.45B
$17.56B
$16.65B
$14.65B
$13.72B
$17.76B
Cost of revenue
$4.03B
$4.09B
$3.55B
$5.27B
$4.17B
$3.78B
$2.85B
$5.91B
Gross profit
$12.56B
$10.94B
$10.9B
$12.29B
$12.48B
$10.88B
$10.87B
$11.86B
Selling, general and administrative
$3.28B
$3.41B
$2.96B
$4.16B
$3.19B
$3.42B
$3.03B
$4.27B
Research and development
$3.02B
$2.81B
$2.49B
$3.21B
$2.55B
$2.48B
$2.2B
$3.04B
Total operating expenses
$8.88B
$7.88B
$6.87B
$9.42B
$8.63B
$7.09B
$7.13B
$9.51B
Operating income
$3.67B
$3.06B
$4.03B
$2.87B
$3.85B
$3.78B
$3.74B
$2.35B
Interest expense
-$662M
-$667M
$0
$0
-$652M
-$654M
$0
$0
Income before taxes
$3.39B
-$653M
$3.17B
-$1.64B
$3.33B
$3.04B
$2.79B
-$10M
Income taxes
$134M
-$407M
$461M
-$2M
-$216M
$141M
-$189M
-$421M
Net income
$3.25B
-$238M
$2.7B
-$1.64B
$3.55B
$2.93B
$2.97B
$418M
Net income attributable to common shareholders
$3.24B
-$248M
$2.69B
-$1.65B
$3.54B
$2.91B
$2.97B
$410M
EBITDA
$6.71B
$5.16B
$5.88B
$5.37B
$7.19B
$5.39B
$6.04B
$4.98B
Basic earnings per share
$0.57
-$0.04
$0.47
-$0.29
$0.62
$0.51
$0.52
$0.07
Diluted earnings per share
$0.56
-$0.04
$0.47
-$0.29
$0.62
$0.51
$0.52
$0.07
Recent news
Company coverage with links to the original publishers.
The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.
The iShares Select Dividend ETF (DVY) is a passively managed fund with $23.65 billion in assets offering exposure to large-cap value stocks. With a 0.38% expense ratio, 3.29% dividend yield, and 17.8% year-to-date return, it presents a medium-risk option for dividend-focused investors. However, alternatives like SCHD and VTV offer lower expense ratios, earning DVY a Zacks ETF Rank of 3 (Hold).
The article recommends Pfizer and PepsiCo as overlooked dividend stocks offering yields above 4% in a market focused on AI and growth. Pfizer is diversifying into oncology with strong acquisition-driven growth, while PepsiCo is recovering from weight-loss drug concerns through international expansion and pricing power. Both stocks offer durability and reliable dividend income for long-term investors.
The global anti-obesity drugs market is valued at USD 8.96 billion in 2026 and projected to reach USD 64.96 billion by 2035 at a 24.71% CAGR. Eli Lilly and Novo Nordisk dominate with strong Q3 2026 results, while Pfizer, Roche, and Amgen are investing billions to compete. Key trends include oral GLP-1 formulations, higher efficacy rates (>20% weight loss), and significant manufacturing capacity investments.
Zacks analysts reviewed three major stocks on November 16, 2026. Visa benefits from strong brand and digital transaction growth but faces profitability pressures from rising expenses. ExxonMobil gains from low-cost production and expansion opportunities but remains exposed to commodity volatility. Pfizer struggles with patent expirations and subdued near-term growth, though pipeline investments in oncology and obesity offer longer-term potential.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Nov 6, 2026
$0.43
Dec 7, 2026
recurring
Jul 24, 2026
$0.43
Sep 1, 2026
recurring
May 8, 2026
$0.43
Jun 12, 2026
recurring
Jan 23, 2026
$0.43
Mar 6, 2026
recurring
Nov 7, 2025
$0.43
Dec 1, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.